Neil Hansen MD, Presenter: Nothing to Disclose

Ryan O'Malley MD, Abstract Co-Author: Nothing to Disclose

Carolyn Lee Wang MD, Abstract Co-Author: Nothing to Disclose

Jordan H. Hankins MD, Abstract Co-Author: Nothing to Disclose

The Learner will obtain the following from this exhibit: 1. Updated knowledge of current clinical and experimental response criteria used to evaluate therapeutic response on interim PET/CT obtained for lymphoma. 2. A review of the evidence supporting the use of these criteria in the clinical and research settings. 3. Experience in how implementing these criteria into clinical practice can better serve patients and referring oncologists.  

Overview of the clinical need for interim PET response criteria in lymphoma patients in order to direct management. Discuss the technical aspects and limitations of quantitative and qualitative response assessment on PET. Literature update on selected response criteria assessments including: - Deauville / 5 Point scale qualitative assessment - Change in SUV max quantitative assessment - Metabolic Tumor Volume and Total Lesion Glycolysis quantitative assessment  

http://abstract.rsna.org/uploads/2014/14007290/14007290_crxd.pdf

Hansen, N, O'Malley, R, Wang, C, Hankins, J, Criteria for Treatment Response on Interim PET/CT in Lymphoma: Update on What the Radiologist Needs to Know.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14007290.html